Abliva AB Interim Report January – September 2024
- Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development -
Press releases
Abliva AB Interim Report January – June 2024
FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility
Abliva AB Interim Report January – March 2024
SEK 46 million raised through preferential rights issue | Preparations for the interim analysis ongoing
Abliva AB Year-End Report January – December 2023
40 Patients Enrolled in Wave 1 of the FALCON Study | Fast Track Designation for KL1333 | Orphan Drug Designation for NV354 in both US and Europe
Abliva AB Interim Report January – September 2023
KL1333 Received FDA Fast Track Designation | The FALCON Study Reached an Important Milestone
Abliva AB Interim Report January – June 2023
The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354
Abliva AB Interim Report January – March 2023
Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
Abliva AB Year-End Report January – December 2022
A successful financing enabled the start of the FALCON study with KL1333
Abliva AB Interim Report January – September 2022
Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases
Abliva AB Interim Report January – June 2022
SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Abliva AB Interim Report January – March 2022
First quarter summary
Abliva AB Year-End Report January – December 2021
"2021 was a defining year for Abliva, focused on portfolio delivering, de-risking our assets and building relationships as we prepared for success in 2022." - Ellen Donnelly, CEO